Early access to experimental SMA drug apitegromab offered before approval
NCT ID NCT06877689
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This expanded access program provides apitegromab, an experimental drug that blocks myostatin to help maintain muscle strength, to eligible patients with spinal muscular atrophy (SMA) before it is officially approved. Participants must be at least 2 years old and have a confirmed diagnosis of 5q SMA. The program aims to offer treatment to those who cannot join other clinical trials and for whom the potential benefit outweighs the risks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apitegromab (a monoclonal antibody that blocks myostatin activation to help maintain muscle strength)
What this could lead to
If successful, this program could provide early access to a treatment that helps preserve muscle function in people with spinal muscular atrophy.
What could go wrong
This is an expanded access program, not a full clinical trial, so data on safety and effectiveness are still limited. Apitegromab is investigational and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.